Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and

    Mixtures: OTEZLA (10 MG 20 MG 30 MG), OTEZLA (10 MG 20 MG 30 MG)Products: OTEZLA (30 MG), OTEZLA TABLET 30 MG
  2. Drug

    Selenium

    go.drugbank.com/drugs/DB11135
    ApprovedInvestigationalVet approved

    Selenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen

    Mixtures: Multi Nt-OX, Prefera OB plus DHACategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: ACTİFED 60 MG/2,5 MG TABLET, ACTİFED 30 MG/5 ML + 1,25 MG/5 ML ŞURUP
  4. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

    Mixtures: TRİVAG 300 MG / 200 MG/ 100 MG OVÜL, 3 ADET, GYNOMAX XL 200 MG/ 300 MG/100 MG VAJINAL OVÜL, 3 ADETCategories: combinations of imidazole derivatives
  5. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.

  6. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas. … This drug is made up of paramagnetic manganese (II) ions combined with the chelating agent _fodipir_ (dipyridoxyl diphosphate, DPDP).

    Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting
  7. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

    Categories: Mammalian target of rapamycin (mTOR) kinase inhibitors
  8. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

    Mixtures: NATMET 120/1000 MG TEDAVI PAKETI, 90+90 ADET, NATMET 120/500 MG TEDAVI PAKETI, 90+90 ADETProducts: NATGEL 120 MG FİLM KAPLI TABLET, 84 ADET, STARLIX TABLET 60 mg
  9. Drug

    Calcium levulinate

    go.drugbank.com/drugs/DB13800
    Approved

    Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation [L2765]. … The relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide [L2765].

    Mixtures: CALCİOSEL 225 mg + 572 mg / 10 mL ENJEKSIYONLUK ÇÖZELTI, CALCİLES 225 MG+572 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  10. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGProducts: LINAGLIPTIN EG, Sansik 5 mg Filmtabletten